News Sentiment

ORMP sentiment intelligence

Oramed Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.03 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-0.2% over one week, +3.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 3.9% over four weeks
Fair value 58.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 39
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 8
Market source 7
TradingKey 4
simplywall.st 4
Seeking Alpha 3
PR Newswire 3
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 16
Balance sheet 4
Capital return 2
Guidance 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Ad Hoc News Direct company coverage

Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback

Oramed Pharmaceuticals (ORMP) stock is reflecting a strategic pivot following the discontinuation of its oral insulin program for type 2 diabetes due to insufficient efficacy. The company, a small-cap clinical-stage biotech, is now focusing its oral drug delivery technology on ot

Tone
Negative 37/100
Event
Market update
Published
17 Jul 2026 17:40
Source
Ad Hoc News
TradingView Direct company coverage

Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP

This article provides financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data snippet from a platform like TradingView, listing company details and market data. The content

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 13:43
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP

This article provides general financial information for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), focusing specifically on its enterprise value to EBIT forward. It indicates that such financial data is available through TradingView, which sources its information from ICE Data S

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 00:12
Source
TradingView
AD HOC NEWS Direct company coverage

Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects

Oramed Pharmaceuticals is drawing investor attention due to its oral drug delivery platform, which aims to develop capsule-based alternatives to injectable biologic drugs. The Nasdaq-listed biotech focuses on clinical-stage development, with a notable project being an oral insuli

Tone
Positive 67/100
Event
Market update
Published
08 Jul 2026 18:34
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr

Oramed Pharmaceuticals, a Nasdaq-listed biotechnology company, is focused on developing oral formulations of injectable drugs for metabolic and liver diseases. The company aims to improve patient convenience and adherence by leveraging proprietary oral delivery platforms that pro

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 14:41
Source
AD HOC NEWS
TradingView Direct company coverage

Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP

This article focuses on the "Price to earnings forward" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), as presented on TradingView. It provides a brief financial overview for the company, indicating key data points and the source of the market and reference data.

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP

This article focuses on the "Price to book forward" metric for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It provides a high-level overview of the company's financial data available on TradingView, listing the market and stock information. The content primarily acts as a placeho

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 18:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP

The article provides a financial metric, "Enterprise value to revenue forward," for Oramed Pharmaceuticals Inc. (NASDAQ: ORMP). It appears to be a stub or a section of a larger financial data page, showing the company's ticker, exchange, and market status. The content itself does

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 10:40
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma

Avraham Gabay, CFO of Oramed Pharmaceuticals Inc's subsidiary, sold 73,360 shares of ORMP on July 1, 2026, reducing his holdings to 671,785 shares. This sale aligns with a trend where Gabay has sold shares but made no purchases over the past year, while the company has seen two i

Tone
Negative 28/100
Event
Market update
Published
03 Jul 2026 00:41
Source
GuruFocus
TradingView Direct company coverage

Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K

Oramed Pharmaceuticals' COO & CBO, Hexter Joshua, sold 137,000 shares of common stock worth $611,431 on July 1, 2026. The transaction was conducted under a Rule 10b5-1 plan adopted on March 30, 2026, with shares sold at a weighted average price of $4.463. Following this sale, Hex

Tone
Negative 30/100
Event
Market update
Published
02 Jul 2026 20:41
Source
TradingView
Stock Titan Direct company coverage

Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise

Oramed Pharmaceuticals' COO and CBO, Joshua Hexter, exercised 50,000 stock options at $3.69 per share and subsequently sold 137,000 common shares at a weighted average price of $4.463 per share. These transactions, which occurred on July 1st and 2nd, 2026, were conducted under a

Tone
Negative 20/100
Event
Market update
Published
02 Jul 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares

Oramed Pharmaceuticals Inc.'s Chief Financial Officer, Avraham Gabay, sold 73,360 shares of common stock on July 1, 2026, at a weighted average price of $4.5085 per share. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following th

Tone
Negative 35/100
Event
Market update
Published
02 Jul 2026 20:41
Source
Stock Titan
TradingView Direct company coverage

Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings

This article provides access to Oramed Pharmaceuticals Inc.'s SEC filings and other financial documents. It lists earnings reports, quarterly (10-Q), and annual (10-K) reports from Q1 FY2021 through Q1 FY2026, highlighting key financial outcomes like net income and strategic deve

Tone
Positive 70/100
Event
Earnings
Published
02 Jul 2026 07:41
Source
TradingView
Investing.com South Africa Direct company coverage

Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com

This article from Investing.com reports on Form 144 filings for ORAMED PHARMACEUTICALS INC. for July 1st. It emphasizes that trading in financial instruments and cryptocurrencies carries significant risks and advises investors to be fully informed before making investment decisio

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 16:39
Source
Investing.com South Africa
Stock Titan Direct company coverage

Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) filed a Form 144 revealing 93,360 shares of Common Stock linked to the vesting of Restricted Stock Units (RSUs) on June 18, 2026. The filing indicates the shares were issued without consideration, with Nasdaq listed as the market and an

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:48
Source
Stock Titan
Stock Titan Direct company coverage

137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144

Oramed Pharmaceuticals has filed a Form 144, indicating proposed sales of 137,000 common shares with an associated value of $658,970.00. The filing also notes 108,000 shares issued from RSU vesting in 2023 and 50,000 shares acquired from employee stock option exercises on July 1,

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 15:39
Source
Stock Titan
Stock Titan Direct company coverage

Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) has updated its corporate bylaws, refining procedures for stockholder action by written consent. Concurrently, Oramed has renegotiated and extended the payment schedule for approximately $36.2 million in debt owed by Scilex Holding Compa

Tone
Neutral 50/100
Event
Balance sheet
Published
30 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A

BML Investment Partners, L.P. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 1,026,269 shares, or 2.5% of Oramed Pharmaceuticals Inc. (ORMP). Braden M. Leonard is identified as the indirect owner through BML Capital Management, LLC. The filing specifies

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 14:34
Source
Stock Titan
TradingView Direct company coverage

Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1)

This article provides financial actuals and estimates for Oramed Pharmaceuticals Incorporated (MUN:OJU1), including income statement, balance sheet, and cash flow data. It also covers analyst price forecasts, historical stock performance, upcoming earnings dates, and key financia

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 20:09
Source
TradingView
TradingView Direct company coverage

Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1)

This article provides financial actuals and analyst estimates for Oramed Pharmaceuticals Incorporated (DUS:OJU1), including income statement, balance sheet, cash flow, and valuation metrics. It offers a stock forecast with max and min estimates, historical price data, and details

Tone
Neutral 50/100
Event
Guidance
Published
26 Jun 2026 06:40
Source
TradingView
Financial Times Direct company coverage

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet – Company Announcement - FT.com

Oramed Pharmaceuticals Inc. issued a letter to shareholders detailing significant developments, including its inclusion in the Russell 2000 and 3000 indexes, substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in cash and asset

Tone
Positive 73/100
Event
Balance sheet
Published
25 Jun 2026 16:35
Source
Financial Times
TradingView Direct company coverage

Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP)

This article provides an overview of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), detailing its stock performance, financial actuals and estimates, and analyst forecasts. As of the article's publication time, ORMP's stock price was $5.00, having increased significantly over the pa

Tone
Positive 76/100
Event
Analyst action
Published
25 Jun 2026 15:40
Source
TradingView
Stock Titan Direct company coverage

ORMP SEC Filings - Oramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Oramed Pharmaceuticals Inc. (ORMP) SEC filings, including 10-K, 10-Q, and 8-K reports. It details recent material events and financial information, such as an $18 million payment from Scilex Holdings Inc. and a declared cash dividen

Tone
Positive 64/100
Event
Balance sheet
Published
21 Jun 2026 17:41
Source
Stock Titan
Morningstar Direct company coverage

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is scheduled to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Indexes. This inclusion will become effective after the close of US markets on Friday, June 26, 2026, and for trading at the market open on Monday, June

Tone
Positive 71/100
Event
Market update
Published
19 Jun 2026 01:40
Source
Morningstar
TradingKey Direct company coverage

Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oramed Pharmaceuticals Inc (ORMP), noting its current valuation score of 8.94 and its ranking within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 1.45, contrasting it with recent high

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:40
Source
TradingKey